The winner effect is an accumulation of previous wins that increase future winning. A primary unanswered question about the winner effect is how do individuals integrate information about previous wins? Dopamine (DA) has been implicated because phosphorylated tyrosine hydroxylase (pTH), the rate-limiting enzyme for DA biosynthesis, is elevated following multiple winning experiences. Moreover, DA receptor blockers and agonists influence aggression when administered prior to male-male contests. In the current study, we administered D1- and D2-like DA receptor antagonists immediately after a contest and examined the development of the winner effect in the territorial California mouse, Peromyscus californicus. During a 3-contest training phase, resident males experienced winning contests, followed immediately by a peripheral injection of either a DA receptor antagonist or vehicle or a handling experience (without injection). The DA receptor antagonists used in this study did not influence locomotion. To assess the cumulative effects of previous winning, males were subjected to a final test contest with a more competitive intruder. The winner effect was significantly decreased by both D1- and D2-like receptor antagonists administered during training. During the test contest, attack behavior was significantly reduced by previous administration of both types of DA receptor antagonists compared with controls. D1-like receptor blockade also diminished chasing behavior, whereas D2-antagonist treated animals continued to pursue opponents. During training against a less competitive intruder, there was no difference in aggressive behaviors between experimental and controls males. Our data indicate that DA activity between contests is concomitant with the competitive advantage gained from multiple winning experiences.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/bne0000043 | DOI Listing |
Hormones (Athens)
January 2025
LABIOEX-Exercise Biology Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, SC, Brazil.
The endocannabinoid system (ECS), regulating such processes as energy homeostasis, inflammation, and muscle function, centers around cannabinoid receptors, including CB1. These receptors are mainly located in the central nervous system and skeletal muscles. Hyperactivity of CB1 receptors is linked to metabolic disorders and chronic inflammation, highlighting their potential as therapeutic targets for muscle hypertrophy and metabolic health.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Urology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Penile metastasis originating from prostate cancer is an extremely rare condition, typically associated with a poor prognosis. Therapeutic approaches are not well established and may require individualized adaptation based on clinical assessment. Radiotherapy is commonly utilized to alleviate symptoms.
View Article and Find Full Text PDFLarge library docking of tangible molecules has revealed potent ligands across many targets. While make-on-demand libraries now exceed 75 billion enumerated molecules, their synthetic routes are dominated by a few reaction types, reducing diversity and inevitably leaving many interesting bioactive-like chemotypes unexplored. Here, we investigate the large-scale enumeration and targeted docking of isoquinuclidines.
View Article and Find Full Text PDFBackground And Purpose: Polycystins (PKD2, PKD2L1) are voltage-gated and Ca -modulated members of the transient receptor potential (TRP) family of ion channels. Loss of PKD2L1 expression results in seizure-susceptibility and autism-like features in mice, whereas variants in PKD2 cause autosomal dominant polycystic kidney disease. Despite decades of evidence clearly linking their dysfunction to human disease and demonstrating their physiological importance in the brain and kidneys, the polycystin pharmacophore remains undefined.
View Article and Find Full Text PDFWorld J Clin Oncol
January 2025
Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States.
Background: Proton pump inhibitors (PPIs) are widely used, including among cancer patients, to manage gastroesophageal reflux and other gastric acid-related disorders. Recent evidence suggests associations between long-term PPI use and higher risks for various adverse health outcomes, including greater mortality.
Aim: To investigate the association between PPI use and all-cause mortality among cancer patients by a comprehensive analysis after adjustment for various confounders and a robust methodological approach to minimize bias.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!